- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
The Role of PCSK9 Inhibitors for Patients with Hyperlipidemia
Zachary T. Bloomgarden, MD, MACE: We know that some individuals will receive a potent statin, or as much of a statin as they can tolerate (because some people develop really burdensome musculoskeletal complaints with statins). Yet, we’ll have evidence of atherosclerotic cardiovascular disease and have LDL (low-density lipoprotein) cholesterol levels [that] are above goal.
For such individuals, we now have a few choices [for treatment]. We can use the bile acid binding resins. We can use ezetimibe. We now can use the PCSK9 (proprotein convertase subtilisin kexin 9) inhibitors, which are tremendously potent agents for lowering LDL cholesterol and seem to be rather well tolerated.
I think this, essentially, represents a huge advance in the way that the dyslipidemia will be treated going forward. There’s the cost issue. There’s all these other things which are so important. So, we have to see how it all plays out, but the fact that we have so many choices is only going to help us to do a better job.
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Downward Morbidity, Mortality Trends Discovered Among Patients With Ovarian Cancer, Liver Metastases
April 24th 2024This study indicates a declining trend in morbidity and mortality rates among patients with ovarian cancer and liver metastases, highlighting the efficacy of surgery and chemotherapy in improving survival outcomes.
Read More
